NCT02326298 - An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) | Biotech Hunter

Enrollment

234

Participants

Timeline

Start Date

December 16, 2014

Primary Completion Date

March 8, 2016

Study Completion Date

October 24, 2018

Conditions

PsoriasisPlaque Psoriasis

Interventions

BIOLOGICAL

Certolizumab Pegol

"* Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous use"

OTHER

Placebo

"* Active Substance: Placebo~* Pharmaceutical Form: Solution for injection in pre-filled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous use"

Trial Locations (30)

37215

Ps0005 508, Nashville

50265

Ps0005 502, West Des Moines

63117

Ps0005 505, St Louis

70809

Ps0005 500, Baton Rouge

77004

Ps0005 501, Houston

87106

Ps0005 507, Albuquerque

92123

Ps0005 504, San Diego

02111

Ps0005 506, Boston

Unknown

Ps0005 597, Edmonton

Ps0005 591, Surrey

Ps0005 596, Ajax

Ps0005 590, Hamilton

Ps0005 593, Toronto

Ps0005 595, Drummondville

Ps0005 594, Québec

Ps0005 553, Náchod

Ps0005 550, Olomouc

Ps0005 551, Ostrava-Poruba

Ps0005 552, Prague

Ps0005 562, Mahlow

Ps0005 565, Witten

Ps0005 569, Lübeck

Ps0005 560, Berlin

Ps0005 561, Dresden

Ps0005 563, Hamburg

Ps0005 568, Hamburg

Ps0005 566, Kiel

Ps0005 580, Orosháza

Ps0005 582, Budapest

Ps0005 581, Pécs

All Listed Sponsors

lead

UCB Biopharma S.P.R.L.

INDUSTRY